Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
Provided By GlobeNewswire
Last update: Jul 8, 2024
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries.
3.42
+0.21 (+6.54%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
14 days ago - ChartmillWhich stocks are moving on Wednesday?Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
16 days ago - ChartmillWhich stocks are moving on Monday?Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
16 days ago - ChartmillKeep an eye on the top gainers and losers in Monday's session.Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
16 days ago - ChartmillMonday's session: gap up and gap down stocksThe market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
